Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) for: Pembrolizumab (Keytruda) for classical Hodgkin lymphoma.
The surveys provide us with the patient and caregiver input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, June 30th and should only take 10 minutes of your time.
